Literature DB >> 27015650

Assessment of the direct cyclotron production of (99m)Tc: An approach to crisis management of (99m)Tc shortage.

Mohammad Reza Aboudzadeh Rovais1, Khosro Aardaneh2, Gholamreza Aslani2, Ali Rahiminejad2, Kamran Yousefi2, Fatemeh Boulouri2.   

Abstract

Nowadays, the cyclotron production of technetium-99m ((99m)Tc) has been increased, due to the worldwide (99m)Tc generator shortage. In the present work, an improved strategy for the production of (99m)Tc, using the proton irradiation of the enriched (100)Mo was developed. The performance of this method in terms of the production yield, chemical purity, radiochemical purity, as well as radionuclide purity was evaluated. The average production yield was measured to be 356MBqμA(-1)h(-1). A good agreement was found between the calculated production yield and the experimental one. The radiochemical separation and total recovery yields of (99m)Tc were 92% and 69%, respectively. The radiochemical and the radionuclide purities of the (99m)Tc were 99% and >99.99% at the end of purification, respectively. The results of quality control tests (QC) support the concept that cyclotron-produced (99m)Tc is suitable for preparation of USP-compliant.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (99m)Tc production; Cyclotron; Simulation; Targetry

Year:  2016        PMID: 27015650     DOI: 10.1016/j.apradiso.2016.03.017

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

Review 1.  Production of novel diagnostic radionuclides in small medical cyclotrons.

Authors:  Mateusz Adam Synowiecki; Lars Rutger Perk; J Frank W Nijsen
Journal:  EJNMMI Radiopharm Chem       Date:  2018-02-20

2.  Detection of Pulmonary Embolism with Gallium-68 Macroaggregated Albumin Perfusion PET/CT: An Experimental Study in Rabbits.

Authors:  Aziz Gültekin; Mustafa Çağdaş Çayır; Ayşe Uğur; Ferda Bir; Doğangün Yüksel
Journal:  Contrast Media Mol Imaging       Date:  2020-06-29       Impact factor: 3.161

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.